Drugs / Bacillus Calmette-Guérin for treatment
Bacillus Calmette-Guérin for treatment
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06747455 | Apr 2025 → Apr 2028 expected | — | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guérin for treatment | “The name of the drug: Bacillus Calmette-Guérin for treatment(BCG).” NCT06747455 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06747455 ↗ |
| Known as | BCG for Therapeutic Use | “Common name: BCG for Therapeutic Use Specification: 60mg/bottle.” NCT06747455 ↗ |
| Known as | BCG for Therapeutic Use ( BI SAI JI ) | “Common name: BCG for Therapeutic Use ( BI SAI JI ) Specification: 60mg (6.0×10\^7CFU)/bottle.” NCT06747455 ↗ |
| Known as | BI SAI JI | “Common name: BCG for Therapeutic Use ( BI SAI JI ) Specification: 60mg (6.0×10\^7CFU)/bottle.” NCT06747455 ↗ |
| Modality | Vaccine | “therapeutic BCG vaccine” NCT06747455 ↗ |
| Route | Other | “given intravesical infusion (experimental drug)” NCT06747455 ↗ |